1 / 14

Principal Investigator: Giuseppe Patti

ARMYDA-5 ( A ntiplatelet therapy for R eduction of MY ocardial D amage during A ngioplasty) Study Prospective, multicenter, randomized trial investigating influence on outcome of in-lab 600 mg clopidogrel loading vs 6-hour pre-PCI treatment – “ARMYDA-PRELOAD”.

marshall-sims
Download Presentation

Principal Investigator: Giuseppe Patti

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence on outcome of in-lab 600 mg clopidogrel loading vs 6-hour pre-PCI treatment – “ARMYDA-PRELOAD” Chairman: Germano Di Sciascio Principal Investigator:Giuseppe Patti Investigators:Vincenzo Pasceri, Giuseppe Colonna,Antonio Montinaro, Leonardo Lassandro Pepe, Francesco Ciccirillo, Laura Gatto, Fabio Mangiacapra, Antonio Tondo, Andrea D’Ambrosio, Annunziata Nusca, Giordano Dicuonzo, Gennaro Sardella, Bibi NGuyen

  2. P=0.041 12% 4% ARMYDA-2 RESULTS Primary end-point 30-day Death, MI, TVR (%) Circulation 2005;111:2099-2106

  3. ARMYDA-5 PRELOAD: BACKGROUND • The ARMYDA-2 trial demonstrated a 61% RR of MACE in patients undergoing PCI pretreated (mean 6 hrs) with 600 mg clopidogrel loading , compared with a 300 mg dose • Concerns about surgical bleeding (with preloading), and/or adequacy of antiplatelet effect (with in-lab loading) GOAL OF THE STUDY • To evaluate safety and effectiveness of a strategy of 600 mg clopidogrel load given in the cath-lab, at the time of PCI, after diagnostic coronaryangiography

  4. ARMYDA-5 PRELOAD: Study design 30 days Medical Rx N= 72 Clopidogrel 600 mg given 4-8 hrs before angio N= 267 N= 409 536Patients with PCI 600 mg Preload N= 204 - Stable angina Primary end point: cardiac death, MI, TVR Randomization or Angiography - NSTE ACS PCI 600 mg in-lab N= 205 Clopidogrel 600 mg at the time of PCI N= 269 undergoing coronary angiography CABG N= 55 1st blood sample 2nd, 3rd, 4th and 5th blood samples Baseline At the time of PCI 2 hrs after PCI 8 and 24 hrs after PCI • CK-MB • Troponin-I • PRU • PRU • PRU • CK-MB • Troponin-I • PRU

  5. ARMYDA-5: STUDY END POINTS • Primary end point • 30-day incidence of cardiac death, MI, target vessel revascularization • (MI definition: post-procedural increase of CK-MB >3 times above UNL in patients with normal • baseline levels of CK-MB; subsequent elevation 50% the baseline value of CK-MB in patients with ACS • and raised baseline CK-MB levels) • Secondary end points • Post-procedural increase of markers of myocardial injury above UNL (CK-MB, troponin I, myoglobin) • Occurrence of any vascular/bleeding complications (Safety secondary end point) • “Point of care” measurement of platelet reactivity at different time points in the two arms

  6. ARMYDA-5 PRELOAD Inclusion criteria - Clopidogrel-naïve pts with stable angina or non-STE ACS undergoing PCIExclusion criteria-Primary PCI- Platelet count <70x103/mL- Pts at high risk of bleeding- Coronary by-pass grafting in the previous 3 months- Therapy with clopidogrel within 10 days

  7. ARMYDA-5 PRELOAD Clinical characteristics N = 409 pts Pre-load N=204 In-lab treatment N=205 P • Age (years) • Male sex • Systemic hypertension • Diabetes mellitus • Hypercolesterolemia • Current smokers • Clinical pattern: • Non-STE ACS • Troponin positive • Previuos MI • Previous PCI • Previous CABG • Multivessel coronary disease • LV ejection fraction 66±9 82% 74% 33% 69% 21% 43% 45% 34% 24% 9% 43% 55±9% 65±10 81% 75% 36% 75% 22% 36% 47% 33% 32% 6% 36% 56±8% 0.29 0.82 0.89 0.56 0.21 0.92 0.18 0.59 0.81 0.10 0.45 0.18 0.22

  8. ARMYDA-5 PRELOAD Procedural features Pre-load N=204 In-lab treatment N=205 P • Vessel treated: • Left main • LAD • LCx • Right coronary • SVG • PCI for restenosis • Lesions B2/C • Multivessel Intervention • No. of stent/patient • Stent diameter (mm) • Stent Length (mm) • Use of DES • Direct Stenting • Stent deployment pressure (atm) • Duration of stent deployment (sec) • Post-dilatation • Glycoprotein IIb/IIIa inhibitors 1% 44% 25% 29% 1% 10% 53% 15% 1.14±0.7 3.15±0.6 20±9 35% 35% 14.8± 2 22±12 34% 19% 2% 43% 26% 28% 1% 11% 54% 16% 1.12±0.6 3.14±0.5 19±10 39% 35% 14.9± 2.1 20±11 34% 20% 0.69 0.96 0.97 0.81 0.69 0.99 0.96 0.91 0.75 0.84 0.28 0.50 0.95 0.62 0.08 0.97 0.82

  9. ARMYDA-5 PRELOAD: Primary end point Adverse events at 30 days (Clopidogrel in-lab load vs preload) In-lab load Preload 20 16 P=0.72 12 Cumulative incidence of MACE (%) 8 4 0 10 15 20 25 30 5 Days after PCI

  10. ARMYDA-5 PRELOAD Individual components of the primary end point at 30 days 20 16 12 In-lab load % of patients 9.3 8.8 Preload 8 4 0.5 0.5 0 0 0 Death MI TVR

  11. ARMYDA-5 PRELOAD: Secondary end point 1-3 times 1-3 times >3 times >3 times 40 75 P=0.83 P=0.85 60 30 45 20 Creatine kinase-MB (%) Troponin-I (%) 30 10 15 0 0 In-lab load Preload In-lab load Preload

  12. ARMYDA-5 PRELOAD: Safety secondary end point 20 16 P=0.42 12 In-labload % of patients 7.8 Preload 8 5.4 4 0 0 0 Major bleeding Minor bleeding

  13. ARMYDA-5 PRELOAD: Platelet reactivity curves Clopidogrel 600 mg 315 290 276±63 265 245±72 P=0.043 224±74 240 227±71 250±75 P=0.01 P2Y12 reaction Units (PRU) 215 212±72 206±73 209±70 182±72 190 165 174±74 Clopidogrel600 mg 140 0 Study entry PCI 2 hrs 8 hrs 24 hrs In-lab load Preload

  14. CONCLUSIONS • ARMYDA-5 PRELOAD indicates that 600 mg “in lab” clopidogrel load pre-PCI does not have unfavorable influence on outcome (vs 6 hrs preload). • Differences in platelet reactivity by aggregometry (at PCI and at 2 hrs) do not translate into different event rates in the “upstream” vs the in-lab strategy. • No bleeding differences and no major bleedings were observed in the 2 arms. • The in-lab strategy may obviate the need of preloading before knowing patients’ anatomy: thus, when indicated, in-lab 600 mg clopidogrel administration can be a safe and effective alternative to pretreatment given several hours pre-PCI.

More Related